Elevating Next Generation Genomic Science and Technology using Machine Learning in the Healthcare Industry

Genomics is an interdisciplinary field of molecular biology that focuses on studying the structure and function of the gene as well as its relation to gene mapping and tailoring of the genome. The techniques of genomics have led to a revolution in the area of clinical medicine and public health. Genomics plays a critical role in health science by identifying targeted genes, precision in treatment, and drug therapies for patients. The tremendous progress in genomics in the healthcare field is due to the high speed, low cost, increased accuracy, and improved sensitivity of its techniques. The next generation of genomics is marked by recent advances in the field, which utilise computational tools, like artificial intelligence and machine learning. Machine Learning (ML) allows computers to learn, filter, and classify data without human intervention. The Next Generation genomic science technology has major applications in the fields of early detection of tumour gene analysis, non-invasive prenatal screening, and genomic tests for childhood and rare disorders. In this article, we have discussed some recent advances in Next-Generation Machine Learning techniques (NGML) in healthcare and summarised their applications in some recent genomic science techniques like Nanopore sequencing, CRISPR-Cas system, and Spatial transcriptomes technique.

Cancer is a genetically driven disease characterised by mutations that lead to abnormal cell growth and division. Genomic science is essential in identifying these mutations. However, recent advances in AI (artificial intelligence) and DL (deep learning) have significantly enhanced complex genomic data analysis, making cancer detection more precise and efficient. AI is not just a tool but a beacon of hope, enabling early detection, diagnosis, and personalized treatment strategies. This survey comprehensively reviews state-of-the-art AI methodologies applied in cancer genomics, focusing on supervised learning, unsupervised learning, and transfer learning techniques. We examine how AI-driven approaches significantly enhance the identification of cancer-related mutations, improve gene expression profiling, and support the development of targeted therapies. Moreover, the survey underscores the potential of AI not only to reduce false positives and negatives but also to streamline diagnostic workflows and, most importantly, predict patient outcomes in real-time. This real-time prediction capability of AI is a significant step forward in cancer care, providing a high level of reassurance to both patients and healthcare professionals about the accuracy of AI-driven cancer diagnostics. However, it's essential to be aware of the challenges, such as limited data availability, model transparency, and integration into clinical settings, which remain significant obstacles to the widespread adoption of AI in cancer genomics. This review highlights current trends, identifies key challenges, and explores future directions in the application of AI to cancer genomic research. The goal is to emphasize the role of AI in accelerating the development of precision medicine, a promising future for cancer care that will significantly improve patient outcomes.

Microbiome analysis has become an important area of study in biomedical and environmental sciences, offering knowledge regarding microbial communities and their interactions. Machine Learning (ML) and Deep Learning (DL) have also played a major role in improving the study of microbiomes by supporting effective processing and classification of high-dimensional metagenomic data. Here, the application of DL methods, including Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), and Autoencoders, is explored in the context of disease prognosis, microbial community typing, environmental microbiome research, and personalised medicine. The challenges, such as limited labelled data, model explainability, and the absence of generalisability, persist despite all the progress. The integration of multiomics data, Explainable AI (XAI), and Federated Learning becomes unavoidable in overcoming these bottlenecks. Future research needs to be focused on developing standardised datasets and scalable AI models for real-time monitoring of the microbiome. Overwhelming these encounters, ML and DL will continue to revolutionise microbiome analysis, foremost to innovation in accurate medicine and biotechnology, besides ecological sustainability. 

The new advances in genome sequencing technologies have produced exponentially greater genomic data, which need scalable and accurate computational methods for genome annotation and assembly. Traditional annotation and assembly procedures are not scalable, accurate, and computationally efficient, which allows the utilisation of Machine Learning (ML) approaches. This chapter thoroughly reviews ML-based procedures for genomic data processing, annotation, and assembly. It describes some of the various ML approaches, from conventional algorithms to deep learning and combination models, and how they improve sequence alignment, feature extraction, and functional analysis of genetic components. The chapter also describes some of the challenges of integrating ML into genomics, including data heterogeneity, model interpretability, and scalability issues. In addition, a comparative assessment of ML-based and traditional genome annotation tools is illustrated, emphasising the superiority of ML models in terms of accuracy and efficiency. 

Machine learning is an essential tool for predicting systems' behavior. Many machine learning algorithms have recently been used to predict the system's changing behavioral pattern. Phase transition is an exciting phenomenon in physics, observed in many molecules and systems, where a sharp structural change occurs with a minor change in an environment like pressure or temperature. It is a significant process to understand the structure of a molecule. The Bayesian algorithm has diverse applications, and in this chapter, its usage is incorporated with the approach of oneclass classification to predict the phase transition in biopolymers. In this study, the algorithm proposed predicts the phase transition of L-alanine polypeptide. This algorithm corroborates the detection of transition parameters or changepoints in temperature-dependent significant frequencies with experimental results. The observed variation of Amide frequencies of the polypeptide is used to confirm the occurrence of a phase transition that causes structural change with the effect of temperature change. 

The analyses of genomic data hold great promise for personalised medicine by allowing predictive diagnosis and treatment. However, this also brings ethical issues on privacy, consent, ownership of data, and genetic discrimination into question. This work discusses the above issues in the background of the evolving legal framework in India and compares the same with international regulations such as HIPAA, GINA, and GDPR. The sensitive nature of genomic data requires robust protection for privacy. However, India does not have any specific guidelines regarding the privacy and ownership of such data, thereby making people very vulnerable to misuse. Issues of transparency in the commercial use of genetic data are raised by the 23andMe case. Informed consent, too, is particularly challenging, especially in rural areas of India, where many participants may not understand the consequences of divulging their genetic information. The ownership disputes that were encountered in the case of Henrietta Lacks and DeCODE Genetics emphasize the need for more refined sets of regulations. Further, even in the insurance sector in India, discrimination based on genetics is often witnessed, which again calls for immediate protection similar to GINA in the U.S. This study thus recommends the following changes in the existing legal framework: introducing genomic-specific legislation in India, working out models of dynamic consent, transparency in data use, and non-genetic discrimination. Such a filling of the gaps shall allow innovation to take place in genomic research, but will guarantee the rights and privacy of the individual.

 Parkinson's Disease (PD) ranks second among the several neurodegenerative diseases. It is characterised by gradual and progressive motor and non-motor symptoms, with highly variable patient responses to pharmacological treatments. Conventional therapeutic procedures frequently result in less-than-ideal outcomes, calling for a more customised approach. The highly tailored treatments provide the right set of circumstances to customise the treatment plans based on the individual's genetic, lifestyle, and environmental factors. Pharmacogenomics is the study that focuses on how individual gene variations influence drug response. It holds great potential to optimise the therapeutic outcome of Parkinson’s Disease (PD). The amalgam of the genetic information with clinical practice can do wonders. However, it also remains a challenge due to its variability and complexity.Moreover, highly sophisticated instruments that can handle and process the enormous volumes of genetic and clinical data are needed to utilise pharmacogenomics fully. As a branch of artificial intelligence, Machine Learning (ML) offers the potential to comprehend large datasets, identify trends, and offer a viable way through the complexity. ML models can be trained to predict individual responsiveness to a particular medication, optimize dosing regimes, and minimize adverse effects by augmenting the pharmacogenomic data. To provide individualised treatment plans for Parkinson's disease, the study investigates the combination of pharmacogenomics and machine learning. The chapter focuses on recent developments in the area, emphasizes the possible advantages of these technologies, and discusses implementation difficulties such as model interpretability, clinical adoption, and data integration. The study also suggests a paradigm for incorporating ML-driven pharmacogenomics into standard clinical practice to improve therapeutic effectiveness and raise patient satisfaction.

The microbiome is a group of microorganisms that live inside the human gut. Imbalances in this intestinal microbiome can lead to the development of Inflammatory Bowel Disease (IBD), because of which it is essential to detect the anomalies in the microbiome metagenomics, which can help in better diagnosis of diseases like Crohn’s disease. Various anomaly and feature selection techniques are available, such as statistical methods (Z-score & IQR, Principal Component Analysis (PCA)) and machine learning techniques (Random Forest, Support Vector Machine (SVM), and K-means clustering). However, due to the high dimensionality of the genomics data, it becomes difficult for these techniques to capture the non-linear relationships of the data, as there is a lot of probabilistic uncertainty associated with it. In this research, we have tried to suggest a study for feature extraction and anomaly detection methods using Variational Autoencoders (VAE) and Generative Adversarial Networks (GAN) to tackle the problem of high dimensionality, proposing a better way to capture non-linear relationships and handle probabilistic uncertainty. The expected outcome for using the VAE and GAN approach is that it can help in better diagnosing and predicting the diseases that are caused by genetic factors, such as Crohn’s disease.

Artificial Intelligence (AI) that includes Machine Learning (ML) and Deep Learning (DL) has revolutionised the various domains of science and genetics. The AIdriven approaches have enabled the rapid analysis of vast genomic datasets, improved the diagnosis of various diseases and drug discoveries, leading to personalised medicines. This chapter explains the role of AI and ML in genetics, exploring their applications along with their benefits, challenges, and future prospects.

This final chapter reiterates the revolutionary contribution of machine learning to genomic medicine and healthcare. It points to the growing role played by AI-based methodologies, especially deep learning architectures such as CNNs, in speeding genomic data analysis, increasing diagnostic accuracy, and making personalised medicine possible. Other methods like reinforcement learning and GANs also continue to revolutionise drug discovery and modeling complex biological interactions. Machine learning applies to a wide range of applications across realms such as cancer diagnosis and the study of rare genetic diseases, with companies such as DeepMind and 23andMe at the forefront of innovation. With technologies such as next-gen sequencing and CRISPR converging with AI, the possibilities for accurate, affordable, and personalised healthcare expand exponentially. The author foresees the synergy between genomics and AI transforming medicine into a more predictive and preventive approach, opening the doors to a new era of healthcare solutions across the lifespan.